Avalyn Pharma General Counsel listed in insider filing

Avalyn Pharma Inc. filed an initial insider ownership report for its General Counsel, Adam H. Golden.

Rhea-AI Filing Summary

Avalyn Pharma Inc. filed an initial insider ownership report for its General Counsel, Adam H. Golden. The Form 3 lists him as an officer but does not report any share transactions or derivative positions, indicating this filing is purely administrative disclosure of insider status rather than trading activity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Avalyn Pharma Inc.'s Form 3 for AVLN report?

The Form 3 for Avalyn Pharma Inc. identifies Adam H. Golden, the company's General Counsel, as a reporting person. It does not list any share transactions or derivative positions, indicating no insider trades are disclosed in this filing.

Who is the reporting person on Avalyn Pharma's AVLN Form 3?

The reporting person is Adam H. Golden, who serves as General Counsel of Avalyn Pharma Inc. He is reported as an officer and not as a director or ten percent owner in this insider ownership filing.

Does the AVLN Form 3 show any insider buying or selling?

No insider buying or selling is shown. The transaction summary reports zero buy, sell, acquire, dispose, and other transactions, with net buy-sell shares at zero, so the filing reflects status, not trading activity.

Are any derivative securities reported in Avalyn Pharma's Form 3?

No derivative securities are reported. The derivative summary is empty and derivativeTransactionCount is zero, meaning the filing does not disclose options, warrants, or other derivative positions for the reporting person.

Does the AVLN Form 3 indicate significant ownership changes?

The Form 3 does not indicate any ownership changes. It shows no transactions, no exercises, gifts, tax withholdings, or restructurings, so it functions as an initial insider designation rather than a record of changes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 06:22 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Golden Adam H.

(Last) (First) (Middle)

105 W FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/29/2026

3. Issuer Name and Ticker or Trading Symbol
Avalyn Pharma Inc. [ AVLN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Douglas Carlson	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)